Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alejandra Rezqallah"'
Autor:
Oriol Mirallas, Berta Martin-Cullell, Víctor Navarro, Kreina Sharela Vega, Jordi Recuero-Borau, Diego Gómez-Puerto, Daniel López-Valbuena, Clara Salva de Torres, Laura Andurell, Anna Pedrola, Roger Berché, Fiorella Palmas, José María Ucha, Guillermo Villacampa, Alejandra Rezqallah, Judit Sanz-Beltran, Rafael Bach, Sergio Bueno, Cristina Viaplana, Gaspar Molina, Alberto Hernando-Calvo, Juan Aguilar-Company, María Roca, Eva Muñoz-Couselo, Alex Martínez-Martí, Ada Alonso, Simeon Eremiev, Teresa Macarulla, Ana Oaknin, Cristina Saura, Elena Élez, Enriqueta Felip, Ángeles Peñuelas, Rosa Burgos, Patricia Gómez Pardo, Elena Garralda, Josep Tabernero, Sònia Serradell, Sònia Servitja, David Paez, Rodrigo Dienstmann, Joan Carles
Publikováno v:
The Lancet Regional Health. Europe, Vol 46, Iss , Pp 101063- (2024)
Summary: Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortal
Externí odkaz:
https://doaj.org/article/510c740dd59f414d89fc0806c8cb60c4
Autor:
Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, David Marmolejo, Alejandra Rezqallah, Caterina Carbonell, Joan Frigola, Ramon Amat, Anna Pedrola, Rodrigo Dienstmann, Enriqueta Felip
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy a
Externí odkaz:
https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc46
Autor:
Santiago Escrivá-de-Romaní, Nadia Saoudi Gonzalez, Oriol Mirallas, María Alejandra Rezqallah Arón
Publikováno v:
BMJ Case Rep
A 44-year-old woman diagnosed with a HER2 positive early breast cancer, receiving neoadjuvant treatment with paclitaxel and targeted agents, trastuzumab together with pertuzumab, presented to the emergency room with gait instability and upper right l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a2fe5fcebb11e3d234ea21d999a286
https://europepmc.org/articles/PMC7449566/
https://europepmc.org/articles/PMC7449566/
Autor:
Eoghan Ruadh Malone, Aaron R. Hansen, Omar Saavedra Santa Gadea, Enriqueta Felip, Lillian L. Siu, Angela Rodriguez, Maria Vieito, Coro Bescos, Ilan Weinreb, Katherine Lajkosz, Anneli Eliason, Alejandra Rezqallah, Susana Aguilar, Alberto Hernando-Calvo, J.D. Assaf, Sarah Jennings, Juan Lorente, Irene Brana, Anna Spreafico, Elena Garralda
Publikováno v:
Journal of Clinical Oncology. 39:6081-6081
6081 Background: Treatment selection based on actionable alterations (AAs) is an appealing strategy for pts with R/M SGT. The GEMS-001 study (NCT02069730) at Princess Margaret Cancer Centre (PM) and the Vall D´Hebron Institute of Oncology (VHIO) pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c55b78218d5eacf3d60df2099ad6d46
https://doi.org/10.1200/jco.2021.39.15_suppl.6081
https://doi.org/10.1200/jco.2021.39.15_suppl.6081